Gunhild Keller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gunhild Keller has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Bokemeyer
Department of Oncology, Haematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication - Friedemann Honecker
Laboratory of Experimental Oncology, Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald-Tumorzentrum, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany
1 shared publication - Hans Joerg Baumann
Department of Respiratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication - Hans Klose
Department of Pneumology, University Hospital of Hamburg, Hamburg, Germany
1 shared publication - Jan K. Hennigs
University Medical Center Hamburg-Eppendorf
1 shared publication - Stefan Kluge
Department of Critical Care Medicine, University Medical Centre Hamburg - Eppendorf, 20246 Hamburg, Germany
1 shared publication
Latest Publications
- Open Access
- 23 May 2011
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 11 (1) , 30
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Background: Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib. Case presentation: Here, we discuss the relevance of previously published cases and add another well-characterised patient who developed pre-capillary PH under long-term therapy with the multi-tyrosine kinase inhibitor dasatinib approved for therapy of chronic myeloic leukaemia (CML) and Philadelphia chromosome positive acute lymphocytic leukaemia (mean time of all patients on dasatinib: 26 months). Hence, we discuss the possibility of dasatinib itself causing PH after long-term therapy and turn specialist's attention to this possible severe side effect. At present, the true incidence of dasatinib-associated PH remains illusive and systematic data regarding haemodynamics are missing. Conclusion: We therefore recommend systematic screening of dasatinib-treated patients for pulmonary hypertension and subsequent collection of haemodynamic data.
- 23 May 2011
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 11 (1) , 30
Open AccessMulti tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Background: Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib. Case presentation: Here, we discuss the relevance of previously published cases and add another well-characterised patient who developed pre-capillary PH under long-term therapy with the multi-tyrosine kinase inhibitor dasatinib approved for therapy of chronic myeloic leukaemia (CML) and Philadelphia chromosome positive acute lymphocytic leukaemia (mean time of all patients on dasatinib: 26 months). Hence, we discuss the possibility of dasatinib itself causing PH after long-term therapy and turn specialist's attention to this possible severe side effect. At present, the true incidence of dasatinib-associated PH remains illusive and systematic data regarding haemodynamics are missing. Conclusion: We therefore recommend systematic screening of dasatinib-treated patients for pulmonary hypertension and subsequent collection of haemodynamic data.